---
title: "Cencora Reaffirms 2026 EPS Outlook Amid Walgreens Shift"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295693023.md"
description: "Cencora reaffirmed its fiscal 2026 adjusted diluted EPS guidance of $17.75 to $17.95, despite a shift in Walgreens volume starting July 2026 that moves certain non-core business to other providers while keeping the prime vendor contract intact. The company stated this transition was already factored into its recent commentary. Analysts maintain a 'Buy' rating with a $395 price target, citing solid financial performance and cash generation, though balance-sheet leverage remains a risk."
datetime: "2026-08-12T16:57:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295693023.md)
  - [en](https://longbridge.com/en/news/295693023.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295693023.md)
generator: "portal-rs"
---

# Cencora Reaffirms 2026 EPS Outlook Amid Walgreens Shift

Cencora ( (COR) ) just unveiled an announcement.

Beginning July 1, 2026, certain Walgreens volume that had been serviced by Cencora outside its prime vendor agreement started moving to other providers, though the core prime vendor contract remained unchanged and continues to account for most of Cencora’s Walgreens-related business. The company noted that this shift had already been factored into its August 5, 2026 commentary on fourth-quarter expectations for the U.S. Healthcare Solutions segment and reaffirmed its adjusted diluted EPS guidance of $17.75 to $17.95 for fiscal 2026, signaling no change to its near-term financial outlook despite the volume transition.

The most recent analyst rating on (COR) stock is a Buy  
 with a $395.00 price target.  
 To see the full list of analyst forecasts on Cencora stock,  
 see the COR Stock Forecast page. 

**Spark’s Take on COR Stock**

According to Spark, TipRanks’ AI Analyst, COR is a Outperform.

The score is driven primarily by solid financial performance and cash generation alongside a positive earnings-call readthrough (raised EPS and operating income growth guidance). The biggest risk tempering the score is balance-sheet leverage in a thin-margin distribution business, while technicals are only moderately supportive (below the 200-day average) and valuation is not especially compelling given a ~23.7 P/E and ~0.75% yield.

To see Spark’s full report on COR stock,  
 click here. 

**More about Cencora**

Cencora, Inc. is a U.S. healthcare solutions and pharmaceutical distribution company that serves large retail pharmacy chains such as Walgreens. The company’s business with Walgreens is largely governed by a prime vendor agreement, which represents the vast majority of the volume Cencora handles for the retailer.

**Average Trading Volume:** 1,640,074

**Technical Sentiment Signal:** Strong Buy

**Current Market Cap:** $62.02B

### Related Stocks

- [COR.US](https://longbridge.com/en/quote/COR.US.md)
- [WBA.US](https://longbridge.com/en/quote/WBA.US.md)

## Related News & Research

- [Empowered Funds LLC Makes New Investment in Cencora, Inc. $COR](https://longbridge.com/en/news/297480534.md)
- [Elizabeth S Campbell Takes Money Off The Table, Sells $3.66M In Cencora Stock](https://longbridge.com/en/news/297065090.md)
- [Livforsakringsbolaget Skandia Omsesidigt Takes $17.57 Million Position in Cencora, Inc. $COR](https://longbridge.com/en/news/297400167.md)
- [Cencora EVP Elizabeth S. Campbell disposes of 11,300 shares worth $3.66 million](https://longbridge.com/en/news/297029611.md)
- [Jupiter Topco LLC Invests $90.86 Million in Cencora, Inc. $COR](https://longbridge.com/en/news/297157386.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**